Libtayo
Phase 3
SanofiLibtayo is one of 102 therapeutic programs targeting Cutaneous Squamous Cell Carcinoma. It is currently in Phase 3.
3
Indications
0
Total Trials
0
Active Trials
101
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
80 competitors in Non-Small Cell Lung Carcinoma
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Abraxane
Bristol-Myers SquibbPhase 3
Alecensa
RochePhase 3
Dostarlimab
IncytePhase 3
Plavix
SanofiPhase 3
Paraplatin
AAvyxa
Phase 3
Alimta
EEagle Vision Pharmaceutical Corp.
Phase 3
DATROWAY
Daiichi SankyoPhase 3
Cabometyx
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for Libtayo. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3
- Company